The FDA issued a warning letter to Medline Inc. over identified issues with its Namic brand angiographic control syringes and manifolds used with radiographic contrast media. The agency said the company must promptly address violations or face potential enforcement actions including seizure, injunctions and civil money penalties. The action underscores ongoing scrutiny of device manufacturing quality systems and compliance in high-use interventional settings.